贝利尤单抗治疗狼疮性肾炎疗效分析

Efficacy of Belizumab in the Treatment of Lupus Nephritis

目的探讨贝利尤单抗治疗狼疮性肾炎的临床疗效和安全性。方法回顾性选取医院2020年2月至2021年2月收治的狼疮性肾炎患者64例,根据用药方法不同分为醋酸泼尼松单独用药组(单独用药组)、醋酸泼尼松联合贝利尤单抗用药组(联合用药组),各32例。结果治疗后,联合用药组患者的肺动脉高压、不列颠群岛狼疮评估小组评分量表评分系统性红斑狼疮疾病活动指数评分量表评分均显著低于单独用药组(P<0.05);联合用药组患者的肾功能指标、炎性因子水平均显著低于单独用药组(P<0.05);联合用药组患者的总有效率为96.88%,显著高于单独用药组的81.25%(χ2=4.332,P<0.05);联合用药组和单独用药组患者的不良反应发生率相当(9.38%比6.25%,χ2=0.000,P>0.05)。联合用药组患者的复发率为3.13%,显著低于单独用药组的18.75%(χ2=4.332,P<0.05)。结论贝利尤单抗治疗狼疮性肾炎疗效显著,可有效改善患者的肾功能、肺动脉高压,降低炎性因子水平,复发率低,安全性好。

Objective To investigate the clinical efficacy and safety of belizumab in the treatment of lupus nephritis.Methods A total of 64 patients with lupus nephritis treated in the hospital from February 2020 to February 2021 were retrospectively selected and divided into prednisone acetate alone group(single drug group)and prednisone acetate combined with belizumab group(combined drug group)according to different medication methods,with 32 cases in each group.Results After treatment,the pulmonary hypertension,the score of British Isles Lupus Assessment Group and the score of Systemic Lupus Erythematosus Disease Activity Index in the combined group were significantly lower than those in the single group(P<0.05).The renal function index and inflammatory factor level in the combined drug group were significantly lower than those in the single drug group(P<0.05).The total effective rate in the combined drug group was 96.88%,which was significantly higher than 81.25%in the single drug group(χ2=4.332,P<0.05).The incidence of adverse reactions was similar between the combined group and the single group(9.38%vs.6.25%,χ2=0.000,P>0.05).The relapse rate of the combined group was 3.13%,which was significantly lower than 18.75%in the single group(χ2=4.332,P<0.05).Conclusion Belizumab is effective in the treatment of lupus nephritis.It can effectively improve the renal function,pulmonary hypertension,reduce the level of inflammatory factors,and has a low recurrence rate and good safety.